ATTENTION: ACTIVE INVESTORS

Market Metrics & Moves Playbook

Issue: "Tech & Biotech Breakouts: AI Infrastructure to Genomic Innovation Leaders"

NEXT 7 DAYS EARNINGS PREVIEW

Editor's Note:

Major developments are emerging in the tech and clean energy sectors as earnings season approaches. Following recent policy discussions at the White House regarding the Department of Government Efficiency (DOGE), our trusted partners have prepared an essential presentation titled "Buy these stocks before DOGE moves". This timely analysis deserves your immediate attention.

As we head into a crucial earnings week, six notable stocks across healthcare, technology, and e-commerce sectors are reporting results that could significantly impact their recent momentum, with all showing substantial gains ranging from 17% to 227% over the past six months. The group includes healthcare innovators Waystar (WAY) and Axsome Therapeutics (AXSM), Chinese e-commerce giant Alibaba (BABA), online retailer Wayfair (W), biotech company SpringWorks (SWTX), and AI data solutions provider Innodata (INOD) - each positioned at interesting inflection points as they prepare to report their latest financial results.

1 WAYSTAR HOLDING CORP (WAY) - Reports Feb 18, Before Market

Healthcare payments software company showing remarkable growth with 82.13% six-month gain and strong analyst support. Trading at $45.35, the company leverages AI-powered solutions for healthcare payment processing with annual revenue of $906.14M. Recent analyst coverage is overwhelmingly bullish with 11 Strong Buy ratings, though current forward P/E of 60.52 suggests high growth expectations.

Key Metrics:

• Market Cap: $7.80B
• Forward PE: 60.52
• 6-Month Change: 82.13%
• Revenue: $906.14M
• Operating Income: $108.27M
• Net Income: -$52.62M

2 AXSOME THERAPEUTICS INC (AXSM) - Reports Feb 18, Before Market

Biopharmaceutical company focused on CNS disorders showing strong momentum with 54.57% six-month gain. Currently at $131.15, the company recently received FDA approval for migraine treatment Symbravo. Analysts project significant upside with average price target of $153.18, though current valuation reflects high growth expectations.

Key Metrics:

• Market Cap: $6.36B
• PE Ratio: N/A
• 6-Month Change: 54.57%
• Revenue: $338.46M
• Operating Income: -$306.22M
• Net Income: -$310.96M

Editor's Note: 

This presentation just crossed my desk from one of our most trusted partners, and I have to say - it's a must-watch.

The #1 Stock for Trump's First 100 Days

Now that President Trump is back in the White House...

The stock market is making new all time highs...

Legendary investor Louis Navellier believes this is just the beginning of Trump's 100-day melt-up.

You should pay attention to what he's saying now...

Because his stock rating system gave a buy rating to ALL of the top 30 performing stocks in the S&P 500 index of Trump's first term...

ALL of them!

Click here to see which stocks his system is rating as a buy right now...

Because this is the same system that has helped him find Amazon in 2003, before it exploded almost 100X higher...

Cisco in 1992, before it jumped 123X higher...

Adobe in 1990, before it jumped 280X higher...&

Apple in 1988, before it jumped 617X higher...

And Microsoft in 1988, before it skyrocketed more than 1,000X.

Click here now because these stocks could turn out to be the top performers of Trump's first 100 days.

YES, I WANT TO WATCH THIS NOW >>

3 ALIBABA GROUP HOLDING LTD (BABA) - Reports Feb 20, Before Market

Chinese e-commerce giant showing strong recovery with 53.80% six-month gain and new dividend initiative. Trading at $124.73, recent meeting between Jack Ma and President Xi signals improving regulatory environment. Attractive valuation at 12.92x forward P/E with new 1.60% dividend yield, though Chinese economic concerns remain.

Key Metrics:

• Market Cap: $302.87B
• Forward PE: 12.92
• 6-Month Change: 53.80%
• Revenue: $135.11B
• Operating Income: $14.89B
• Net Income: $12.06B

4 WAYFAIR INC (W) - Reports Feb 20, Before Market

Online furniture retailer showing mixed performance with 17.34% six-month gain but negative yearly returns. At $49.41, company focuses on cost optimization and margin improvement amid competitive pressures. High forward P/E of 117.95 and significant short interest indicate market skepticism despite operational improvements.

Key Metrics:

• Market Cap: $6.19B
• Forward PE: 117.95
• 6-Month Change: 17.34%
• Revenue: $11.84B
• Operating Income: -$516M
• Net Income: -$538M

5 SPRINGWORKS THERAPEUTICS INC (SWTX) - Reports Feb 20, Before Market

Clinical-stage biotech company demonstrating solid performance with 53.80% six-month gain. Trading at $57.43, recent FDA approval for GOMEKLI provides significant catalyst. Unanimous analyst Buy ratings with 25% upside to average target of $71.80, though typical biotech development risks persist.

Key Metrics:

• Market Cap: $4.27B
• Forward PE: 322.58
• 6-Month Change: 53.80%
• Revenue: $135.49M
• Operating Income: -$295.25M
• Net Income: -$275.16M

6 INNODATA INC (INOD) - Reports Feb 20, After Market

AI/ML data solutions provider showing exceptional momentum with 227.69% six-month gain. At $53.83, company benefits from strong AI industry tailwinds. Currently trading above average analyst price target of $49.00, with insider selling and P/E of 88.26 suggesting potential valuation concerns.

Key Metrics:

• Market Cap: $1.56B
• PE Ratio: 88.26
• 6-Month Change: 227.69%
• Revenue: $137.39M
• Operating Income: $15.04M
• Net Income: $20.02M

Data Sources:

  • • Yahoo Finance
  • • Financial Modeling Prep
If this article makes sense,
YOU NEED TO WATCH THIS BELOW...

looking for opportunities?

YOU NEED TO CLICK BELOW...

Buy these stocks before DOGE moves

Just a few days after the inauguration, my firm issued an urgent and very specific warning about Donald Trump and Elon Musk's real agenda...

Put simply, we claimed that Elon had secured himself a role within the administration to oversee the rollout of powerful new AI technology.

More than that... we predicted the shortlist of tech firms involved in the rollout could create enormous wealth, starting immediately.

It turns out... we were right.

Since we first published our warning just weeks ago, Elon has become a "special government employee", and his Department of Government Efficiency has begun pushing his agenda.

He's wants to pursue an "AI-first" strategy... and he's even deploying his own "AI agents" inside the Federal government.

The problem is... our prediction is coming true much faster than even we thought possible.

Which means you could be running out of time to take a position in the stocks we think will rise fastest as a result of Elon's DOGE agenda.

Right now, the media is reporting every step Elon takes in a frenzy of excitement.

But no one is showing you how to capitalize on what's happening.

If you're quick, you still have time to take advantage.

That's why I'm reaching out to you today – to give you another (potentially final) chance to prepare, before Elon's real plans become front page news.

Buy these stocks before Elon's next move

Regards,

Rob Spivey
Director of Research, Altimetry

P.S. You may never have heard of my firm before today. We're a Boston-based financial think tank, and have consulted with the Pentagon, the FBI, Harvard and many of Wall Street's biggest money managers follow our work.

But we're stepping forward today to share our research directly with you, for reasons I explain right here.

Newsletter Content

Former pit trader exposes "824% pattern"

Government reports are creating predictable moves...

The numbers don't lie. Market moves are 824% larger on specific, predictable days. A former pit trader has broken down exactly why this is happening...

EXPOSED: Wall Street's true crypto agenda

Wall Street's new crypto playbook leaked...

This wasn't supposed to get out. Major financial institutions are executing a carefully planned crypto strategy - and it's nothing like previous cycles...

The AI war just turned real

Market veteran issues urgent AI warning...

Meta: billion AI investment. Tesla: 8% revenue drop. Chinese AI: Major breakthrough. Fed: Changed inflation outlook. These four events happened within 24 hours...

Disclaimer

Market Movers Playbook, a brand under Market Insiders Media dba, operates under the parent company Sandpiper Marketing Group, LLC. Please be advised that Market Movers Playbook is not registered as an investment adviser or broker-dealer with the United States Securities and Exchange Commission or any state regulatory agency. We rely on the "publisher's exclusion" from the definition of investment adviser as set forth in Section 202(a)(11) of the Investment Advisers Act of 1940, as amended, as well as corresponding state securities laws. Consequently, Market Movers Playbook does not offer or provide personalized investment advice. The information we provide is based on our opinions, statistical and financial data, and independent research of public information. Our materials are intended for informational purposes only, and no mention of a specific security in any of our content constitutes a recommendation to buy, sell, or hold that or any other security. Any information deemed to be investment opinion is impersonal and not tailored to the investment needs of any individual. Please be aware that Market Movers Playbook does not promise, guarantee, or imply that any information provided through our websites, newsletters, reports, or printed material will result in profit or loss. We strongly encourage you to seek personal advice from your professional investment, tax, or legal advisors and to conduct your own due diligence and independent investigations before acting on any information we publish or making any investment decision. Only you and your professional advisors can determine the level of risk appropriate for you. Penny stocks, in particular, are inherently speculative investments, and you should be prepared to lose your entire investment. Employees, owners, and/or writers of Market Movers Playbook may own positions in the equities, options, and/or securities mentioned in our content. However, no associated employees will intentionally engage in any transaction that directly or indirectly competes with the interests of our subscribers. Market Movers Playbook may be compensated for publishing information about companies referred to in our reports, newsletters, and websites, and we provide full disclosure of such compensation. Furthermore, please note that any content marked as "Sponsor" may be paid for and is not endorsed or warranted by our staff or company. The content in our emails is for educational or entertainment use and is not a substitute for professional advice or an offer to buy or sell any securities. Neither the publisher nor the editors are registered investment advisors (RIA's) and do not provide personalized counseling. Be sure to conduct your own careful research and consult with your advisors before taking any action based on our content. By opening our emails or clicking any links contained therein, you are reconfirming your opt-in status, which is part of your free subscription.